S9511: A southwest oncology group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 2, 2010, Pages 117-120

  Blanke, Charles D ^a   Chansky, Kari ^b   Christman, Kathy L ^c   Hundahl, Scott A ^d   Issell, Brian F ^e   Van Veldhuizen, Peter J ^f   Budd, G Thomas ^g   Abbruzzese, James L ^h   MacDonald, John S ⁱ  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c Greenville Community Clinical Oncology Program   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SCRIPPS HEALTH   (United States)

^f UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Chemotherapy; Gastric neoplasms; Trimetrexate

Indexed keywords

ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; TRIMETREXATE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG FATALITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EMBOLISM; FATIGUE; FEMALE; HUMAN; HYPOKALEMIA; INFECTION; LETHARGY; LOADING DRUG DOSE; LOWER ESOPHAGUS SPHINCTER; LYMPHOCYTOPENIA; MALAISE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PHYSICAL PERFORMANCE; STOMACH ADENOCARCINOMA; STOMACH PERFORATION; STOMATITIS; THROMBOSIS; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TRIMETREXATE; YOUNG ADULT;

EID: 77951049357     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318199fb84     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer. 1993;72:37-41.
3. Ajani JA. Standard chemotherapy for gastric carcinoma: is it a myth? J Clin Oncol. 2000;18:4001-4003.
4. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: the V-325 Study Group. J Clin Oncol. 2006;24:4991-4997.
5. Cadman E, Heimer R, Benz C. The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem. 1981;256:1695-1704.
6. Bertino JR, Sawicki WL, Lindquist CA, et al. Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res. 1997;337:327-328.
7. Klein HO. Long-term results with FAMTX in advanced gastric cancer. Anticancer Res. 1989;9:1025-1026.
8. Weir E, Cashmore A, Dreyer R, et al. Pharmacology and toxicity of a potent "nonclassical" 2,4-diamino quinazoline folate antagonist, trimetrexate, in normal dogs. Cancer Res. 1982;42:1696-1702.
9. O'Dwyer P, DeLap R, King S, et al. Trimetrexate: clinical development of a nonclassical antifolate. Natl Cancer Inst Monogr. 1987;5:105-109.
10. Kamen B, Cashmore A, Dreyer R, et al. Uptake and efficacy of trimetrexate, a nonclassical antifolate in methotrexate resistant leukemia cells in vitro. Biochem Pharmacol. 1984;33:1697-1699.
11. Romanini A, Li W, Colofiore J, et al. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil in CCRF-CEM cells. J Natl Cancer Inst. 1992;84:1033-1038.
12. Elliot WL, Howard CT, Dykes DJ, et al. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice. Cancer Res. 1989;49:5586-5590.
13. Sobrero A, Romanini A, Russello O, et al. Sequence dependent enhancement of HCT-8 cell kill by trimetreate and fluoropyrimidines: implications for the mechanism of this interaction. Eur J Cancer Clin Oncol. 1989;25:977-982.
14. Leopold WR, Dykes D, Griswold DP. Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, vincristine, cytoxan, 6-thioguanine, cisplatin or 5-fluorouracil against intraperitoneally implanted p388 leukemia. Natl Cancer Inst Monogr. 1987;5:99-104.
15. Grochow LB, Noe DA, Ettinger DS, et al. A phase I trial of trimetrexate glucuronate (NSC-352122) given every 3 weeks: clinical pharmacology and pharmacodynamics. Cancer Chemother Pharmacol. 1989;24:314-320.
16. Grochow LB, Noe DA, Dole GB, et al. Phase I trial of trimetrexate glucuronate on a five day bolus schedule: clinical pharmacology and pharmacodynamics. J Natl Cancer Inst. 1989;81:124-130.
17. Stewart JA, McCormick JJ, Tong W, et al. Phase I clinical and pharmacokinetic study of trimetrexate using a daily x 5 schedule. Cancer Res. 1988;48: 5029-5038.
18. Allegra CJ, Jenkins J, Weiss RB, et al. A phase I and pharmacokinetic study of trimetrexate using a 24 hour continuous infusion schedule. Invest New Drugs. 1900;8:159-166.
19. Conti JA, Kemeny N, Seiter K, et al. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol. 1994;12:695-700.
20. Blanke CD, Kasimis B, Schein P, et al. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol. 1997;15:915-920.
21. Szelenyi H, Hohenberger P, Lochs H, et al. Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of AIO. Oncology. 2000;58: 273-279.
22. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drug. 1992;10:239-253.
23. Common Toxicity Criteria (CTC). (Ed 2.0). Natl Cancer Inst Cancer Ther Eval Prog. 1999.
24. Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin, and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999;80:269-272.
25. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358:36-46.
26. Ajani JA, Baker J, Pisters PWT, et al. CPT-11 plus cisplatin in advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer. 2002;94:641-646.
27. Park SH, Nam E, Park J, et al. Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil versus cisplatin plus ILF combination chemotherapy for advanced gastric cancer. Ann Oncol. 2008;19:729-733.
28. Blanke CD, Shultz J, Cox J, et al. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. Ann Oncol. 2002;13:87-91.
29. Punt CJA, Blanke CD, Zhang J, et al. Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorecal cancer. Ann Oncol. 2002;13:92-94.
30. Dragovich T, McCoy S, Urba S, et al. SWOG 0127: phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas. J Clin Oncol. 2006;24:4922-4927.
31. Iqbal S, Goldman B, Lenz HJ, et al. S0413: a phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients with advanced or metastatic gastric cancer [Abstract 4621]. Proc Am Soc Clin Oncol. 2007;25:227s.
32. Doi T, Koizumi W, Siena S, et al. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer [Abstract 1036]. Proc Am Soc Clin Oncol. 2003;22:2003.